## Data Sheet (Cat.No.T16434)



#### PAT-048


### **Chemical Properties**

CAS No.: 1359983-15-5

Formula: C22H18CIF2N3O2S

Molecular Weight: 461.91
Appearance: N/A

Storage:  $0-4^{\circ}\text{C}$  for short term (days to weeks), or  $-20^{\circ}\text{C}$  for long term (months).



# **Biological Description**

Description	PAT-048 is an effective and selective autotaxin inhibitor. PAT-048 reduces dermal fibrosis in vivo. PAT-048 also inhibits IL-6 mRNA expression but displays no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in the lung fibrosis model. PAT-048 has an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma.
Targets(IC <sub>50</sub> )	Autotaxin, in mouse plasma: 200 nM(IC90)

### **Solubility Information**

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble	

#### **Preparing Stock Solutions**

	1mg	5mg	10mg
1 mM	2.165 mL	10.825 mL	21.649 mL
5 mM	0.433 mL	2.165 mL	4.33 mL
10 mM	0.216 mL	1.082 mL	2.165 mL
50 mM	0.043 mL	0.216 mL	0.433 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

#### Reference

- 1. Castelino FV, et al. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68(12):2964-2974.
- 2. Black KE, et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. 2016 Jun;30(6):2435-50.

Page 1 of 2 www.targetmol.com

### Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only  $\cdot$  Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com